Literature DB >> 19498444

Mdm2-mediated ubiquitylation: p53 and beyond.

J-C Marine1, G Lozano.   

Abstract

The really interesting genes (RING)-finger-containing oncoprotein, Mdm2, is a promising drug target for cancer therapy. A key Mdm2 function is to promote ubiquitylation and proteasomal-dependent degradation of the tumor suppressor protein p53. Recent reports provide novel important insights into Mdm2-mediated regulation of p53 and how the physical and functional interactions between these two proteins are regulated. Moreover, a p53-independent role of Mdm2 has recently been confirmed by genetic data. These advances and their potential implications for the development of new cancer therapeutic strategies form the focus of this review.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19498444     DOI: 10.1038/cdd.2009.68

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  141 in total

1.  Pattern of expression of p53, its family members, and regulators during early ocular development and in the post-mitotic retina.

Authors:  Linda Vuong; Daniel E Brobst; Anisse Saadi; Ivana Ivanovic; Muayyad R Al-Ubaidi
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-07-20       Impact factor: 4.799

Review 2.  Functional proteomics to dissect tyrosine kinase signalling pathways in cancer.

Authors:  Walter Kolch; Andrew Pitt
Journal:  Nat Rev Cancer       Date:  2010-08-19       Impact factor: 60.716

3.  Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loop.

Authors:  X Zhang; W Wang; H Wang; M-H Wang; W Xu; R Zhang
Journal:  Oncogene       Date:  2012-07-09       Impact factor: 9.867

Review 4.  The p53 orchestra: Mdm2 and Mdmx set the tone.

Authors:  Mark Wade; Yunyuan V Wang; Geoffrey M Wahl
Journal:  Trends Cell Biol       Date:  2010-02-19       Impact factor: 20.808

5.  SUMO-specific protease 2 in Mdm2-mediated regulation of p53.

Authors:  M Jiang; S-Y Chiu; W Hsu
Journal:  Cell Death Differ       Date:  2010-12-24       Impact factor: 15.828

6.  Qualitative network modeling of the Myc-p53 control system of cell proliferation and differentiation.

Authors:  Baltazar D Aguda; Yangjin Kim; Hong Sug Kim; Avner Friedman; Howard A Fine
Journal:  Biophys J       Date:  2011-11-01       Impact factor: 4.033

Review 7.  Translating p53 into the clinic.

Authors:  Chit Fang Cheok; Chandra S Verma; José Baselga; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2010-10-26       Impact factor: 66.675

8.  Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

Authors:  Karen Fernandez; Yelda Serinagaoglu; Sue Hammond; Laura T Martin; Paul T Martin
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

Review 9.  20 years studying p53 functions in genetically engineered mice.

Authors:  Lawrence A Donehower; Guillermina Lozano
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

10.  Necdin enhances myoblasts survival by facilitating the degradation of the mediator of apoptosis CCAR1/CARP1.

Authors:  Stephanie François; Cristina D'Orlando; Tiziana Fatone; Thierry Touvier; Patrizia Pessina; Raffaella Meneveri; Silvia Brunelli
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.